Souhaitez-vous accéder aux communiqués récents ?

Insurance claims show U.S. babesiosis incidence may be 10x CDC estimates; 60 Degrees links chronic fatigue and plans 2026 NDA for tafenoquine treatment.

Following its successful launch on May 15, featuring the highly-anticipated “MAHA Commission Report” spearheaded by the Health and Human Services Secretary

60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.

Belleville, Illinois, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Allsup, the nation’s leading provider of Social Security Disability Insurance (SSDI) representation services, is shining a light on Cervical...

London, England, July 24, 2024 (GLOBE NEWSWIRE) -- Airfinity has reduced its sales projections for vaccines against Respiratory Syncytial Virus (RSV) for older adults in the US from $4.7bn per year...

Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...

TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...

Washington, DC, May 07, 2024 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is celebrating the 25th year of the CDC’s National Asthma Control Program (NACP) on World Asthma...

BATON ROUGE, La., April 09, 2024 (GLOBE NEWSWIRE) -- Thanks to a $550,000 National Science Foundation Partnership for Innovation grant—the largest NSF PFI grant ever awarded to LSU—LSU Chemical...

NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention...